Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab in patients with Cervical Adenocarcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.